Biogen Inc (BIIB.OQ)
Drugmaker Biogen Inc's quarterly revenue missed analysts' estimates on Tuesday as it had disappointing sales of its promising drug Spinraza to treat spinal muscular atrophy because fewer new patients used the expensive treatment.
* Biogen shares pare losses (Adds conference call, analysts comments; updates shares)
April 24 Drug developer Biogen Inc reported a 57 percent jump in quarterly profit on Tuesday, helped by higher sales of its spinal muscular atrophy drug, Spinraza.
* QTRLY SPINRAZA REVENUE OF $364 MILLION VERSUS $47 MILLION REPORTED LAST YEAR
Biogen Inc struck a $1 billion neurology drug development deal with Ionis Pharmaceuticals on Friday, expanding a partnership that developed the company's potential blockbuster drug for spinal muscular atrophy.
BRIEF-Biogen And Ionis Expand Strategic Collaboration To Develop Drug Candidates For A Broad Range Of Neurological Diseases
* BIOGEN AND IONIS EXPAND STRATEGIC COLLABORATION TO DEVELOP DRUG CANDIDATES FOR A BROAD RANGE OF NEUROLOGICAL DISEASES
* Comprises equity investment in Ionis plus upfront payment (Adds background, share movement)
April 20 Drugmaker Biogen Inc said on Friday it would pay Ionis Pharmaceuticals Inc $1 billion in cash as part of a new ten-year agreement to develop medicines for a broad range of neurological diseases including dementia.
SEOUL Samsung C&T Corp, de facto holding company of Samsung Group, is considering raising up to 3 trillion won ($2.8 billion) to buy a 30 percent stake in sub-subsidiary Samsung Bioepis Co Ltd, a South Korean TV channel reported on Monday.
SEOUL, April 9 Samsung C&T Corp, de facto holding company of Samsung Group, is considering raising up to 3 trillion won ($2.8 billion) to buy a 30 percent stake in sub-subsidiary Samsung Bioepis Co Ltd, a South Korean TV channel reported on Monday.
|Johnson & Johnson (JNJ.N)||$128.01||+1.25|
|Pfizer Inc. (PFE.N)||$36.85||+0.17|
|Novartis AG (NOVN.S)||CHF76.10||+0.86|
|Merck & Co., Inc. (MRK.N)||$59.41||-0.22|
|Roche Holding Ltd. (ROG.S)||CHF218.10||+0.35|
|Roche Holding Ltd. (RO.S)||CHF223.00||+0.40|
|Bayer AG (BAYGn.DE)||€97.34||-0.13|
|Bayer AG (BAYE.F)||--||--|
|Sanofi SA (SASY.PA)||€66.31||+0.44|
|GlaxoSmithKline plc (GSK.L)||1,436.80||+24.60|